Zacks: Analysts Forecast Nu Skin Enterprises, Inc. (NYSE: NUS) to Report Quarterly Sales of $610.69 Million


Wall Street analysts expect Nu Skin Enterprises, Inc. (NYSE:NUS – Get Rating) to report sales of $610.69 million for the current quarter, Zacks reports. Two analysts released earnings estimates for Nu Skin Enterprises, with the highest sales estimate of $614.87 million and the lowest estimate of $606.50 million. Nu Skin Enterprises reported sales of $704.06 million in the same quarter last year, suggesting a negative 13.3% year-over-year growth rate. The company is expected to announce its next results on Monday, January 1.

According to Zacks, analysts expect Nu Skin Enterprises to report annual sales of $2.56 billion for the current fiscal year, with estimates ranging from $2.55 billion to $2.58 billion. For the next fiscal year, analysts expect the company to post sales of $2.62 billion, with estimates ranging from $2.59 billion to $2.66 billion. Zacks sales calculations are an average average based on a survey of sell-side research companies that cover Nu Skin Enterprises.

Nu Skin Enterprises (NYSE:NUS – Get Rating) last released its results on Wednesday, May 4. The company reported earnings per share of $0.76 for the quarter, beating analyst consensus estimates of $0.73 by $0.03. The company posted revenue of $604.90 million in the quarter, versus a consensus estimate of $579.70 million. Nu Skin Enterprises achieved a return on equity of 22.05% and a net margin of 5.28%. The company’s revenue for the quarter was down 10.7% year over year. During the same period a year earlier, the company posted earnings per share of $0.91.

Several equity research analysts have recently weighed in on NUS shares. Jefferies Financial Group raised its target price on Nu Skin Enterprises from $61.00 to $75.00 in a Thursday, February 17 report. StockNews.com downgraded Nu Skin Enterprises from a “buy” rating to a “hold” rating in a Friday, May 13 research report. DA Davidson raised its price target on Nu Skin Enterprises from $47.00 to $50.00 and gave the stock a “neutral” rating in a Thursday, February 17 research report. TheStreet downgraded Nu Skin Enterprises shares from a “b” rating to a “c+” rating in a Friday, February 18 research note. Finally, Zacks Investment Research upgraded Nu Skin Enterprises shares from a “hold” rating to a “strong-buy” rating and set a price target of $57.00 for the company in a Tuesday, March 29 report. . Three investment analysts have assigned the stock a hold rating, one has issued a buy rating and one has assigned the stock a strong buy rating. Based on MarketBeat data, Nu Skin Enterprises has an average rating of “Buy” and a consensus price target of $60.60.

In other news, CEO Ryan S. Napierski sold 25,000 shares of Nu Skin Enterprises in a trade dated Wednesday, May 25. The stock was sold at an average price of $44.91, for a total transaction of $1,122,750.00. As a result of the sale, the CEO now directly owns 122,683 shares of the company, valued at $5,509,693.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, accessible via the SEC’s website. Additionally, Chairman Steven Lund sold 925 shares in a trade that took place on Wednesday, May 18. The shares were sold at an average price of $46.07, for a total transaction of $42,614.75. Following the sale, the president now directly owns 179,449 shares of the company, valued at approximately $8,267,215.43. The disclosure of this sale can be found here. Insiders sold a total of 66,125 shares of the company valued at $3,009,855 over the past three months. Insiders of the company own 2.80% of the shares of the company.

A number of hedge funds have recently changed their positions in the business. Aurora Investment Counsel increased its stake in Nu Skin Enterprises shares by 1.5% in Q1. Aurora Investment Counsel now owns 25,274 shares of the company worth $1,210,000 after acquiring 362 additional shares in the last quarter. Verity Asset Management Inc. increased its stake in Nu Skin Enterprises by 8.3% during the first quarter. Verity Asset Management Inc. now owns 9,270 shares of the company valued at $444,000 after buying 713 additional shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings of Nu Skin Enterprises shares by 20.3% in the first quarter. The Manufacturers Life Insurance Company now owns 517,687 shares of the company worth $24,787,000 after purchasing an additional 87,502 shares last quarter. Guggenheim Capital LLC increased its holdings of Nu Skin Enterprises shares by 5.8% in the first quarter. Guggenheim Capital LLC now owns 19,671 shares of the company worth $942,000 after purchasing an additional 1,077 shares last quarter. Finally, Goldman Sachs Group Inc. increased its position in Nu Skin Enterprises shares by 48.9% in the first quarter. Goldman Sachs Group Inc. now owns 393,484 shares of the company worth $18,841,000 after buying an additional 129,256 shares in the last quarter. Institutional investors and hedge funds hold 93.79% of the company’s shares.

NYSE: NUS opened at $46.91 on Friday. The company has a debt ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.72. Nu Skin Enterprises has a 52 week minimum of $39.40 and a 52 week maximum of $62.70. The company has a market capitalization of $2.36 billion, a price-earnings ratio of 17.37 and a beta of 1.23. The company’s 50-day moving average is $46.49 and its 200-day moving average is $48.08.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 8. Shareholders of record on Friday, May 27 will receive a dividend of $0.385. The ex-date of this dividend is Thursday, May 26. This represents an annualized dividend of $1.54 and a dividend yield of 3.28%. Nu Skin Enterprises’ dividend payout ratio is currently 57.04%.

Nu Skin Enterprises Company Profile (Get a rating)

Nu Skin Enterprises, Inc develops and distributes beauty and wellness products worldwide. It provides skin care systems, including ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems and ageLOC LumiSpa skin cleansing and treatment devices; and ageLOC Boost, plus a range of other cosmetic and personal care products.

See also

Get a Free Copy of Zacks’ Research Report on Nu Skin Enterprises (NUS)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

Earnings history and estimates for Nu Skin Enterprises (NYSE: NUS)



Receive daily news and reviews for Nu Skin Enterprises – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Nu Skin Enterprises and related companies with MarketBeat.com’s free daily email newsletter.